AstraZeneca reached the cooperation over $700 million to treat fatal cardiomyopathy
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
AstraZeneca reached the cooperation over $700 million to treat fatal cardiomyopathy
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
AstraZeneca reached the cooperation over $700 million to treat fatal cardiomyopathy.
On March 1, 2022, Alexion, a rare disease-focused company under AstraZeneca, announced the completion of an exclusive global collaboration and license agreement with Neurimmune for NI006.
NI006 is an investigational humanized monoclonal antibody currently under development in Phase 1b clinical trials for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a systemic, progressive and fatal disease that can lead to progressive heart failure and death within four years of diagnosis.
Globally, there are an estimated 300,000 to 500,000 patients with ATTR-CM. Due to aging or genetic mutation, the TTR amyloid protein is misfolded and deposited in the myocardium as amyloid fibrils, thereby impairing the normal function of the corresponding organs and tissues.
The increase in TTR protein fibrils leads to more tissue damage and disease progression, resulting in reduced quality of life and eventual death.
NI006 specifically targets misfolded transthyretin, which is expected to treat patients with advanced ATTR-CM by clearing amyloid fibril deposits in the heart, targeting the pathological cause of ATTR-CM. Preclinical models demonstrate that NI006 induces clearance of pathological ATTR.
Under the terms of the agreement, Alexion receives an exclusive worldwide license to develop, manufacture and commercialize NI006.
NI006 adds a novel and complementary approach to AstraZeneca and Alexion’s pipeline of investigational therapies focused on amyloidosis. Alexion pays Neurimmune $30 million upfront.
Neurimmune is also eligible to receive up to $730 million in development, regulatory and commercial milestone payments, as well as royalties on net sales of future approved drugs.
Neurimmune will continue to be responsible for completing Phase 1b clinical trials of the current drug, and Alexion will pay certain trial fees and will be responsible for further future clinical development, manufacturing and commercialization activities.
References:
[1] AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement to develop and commercialise NI006. Retrieved March 1, 2022, from https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/astrazeneca-and-neurimmune-close-deal-for-ni006.html
AstraZeneca reached the cooperation over $700 million to treat fatal cardiomyopathy
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
